![]() 65% of the amount by which the costs of the case exceed the standard Diagnosis-Related Group (DRG) payment (including the adjustment to the relative weight under Section 3710 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act).65% of the operating outlier threshold for the claim.See the Federal Register announcement for more information about the revoked EUA and NDA approval.įor eligible cases, the NCTAP is equal to the lesser of these: VEKLURY® (remdesivir): On January 21, 2022, the FDA approved a supplemental New Drug Application (NDA) for VEKLURY, which expanded its use from adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease.PAXLOVID remains available under the EUA to treat eligible pediatric patients. On May 25, 2023, the FDA approved PAXLOVID to treat eligible adult patients.Review the Fact Sheet for Health Care Providers: EUA for PAXLOVID for more information about the limits and conditions for pharmacists prescribing PAXLOVID. ![]() ![]() On July 6, 2022, the FDA revised the EUA to let pharmacists prescribe and dispense PAXLOVID to eligible patients without seeing a doctor or other clinician.On December 23, 2021, the FDA issued an EUA for PAXLOVID for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients at high risk for progression to severe COVID-19, including hospitalization or death.PAXLOVID TM (nirmatrelvir co-packaged with ritonavir):.Olumiant ® (baricitinib): On November 19, 2020, the FDA issued (latest update October 27, 2022) an EUA for the use of Olumiant for the treatment of suspected or laboratory confirmed COVID-19 in certain hospitalized patients.Lagevrio (molnupiravir): On December 23, 2021, the FDA issued (latest update February 1, 2023) an EUA for molnupiravir for the treatment of mild-to-moderate COVID-19 in certain adults who are at high-risk for progression to severe COVID-19, including hospitalization or death.Review the Fact Sheet for Healthcare Providers: EUA for Kineret for more information about the limits and conditions for pharmacists prescribing Kineret. Kineret ® (anakinra): On November 8, 2022, the FDA issued an EUA for Kineret injection for the treatment of COVID-19 in hospitalized adults with positive results of direct SARS-CoV-2 viral testing with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR).GOHIBIC (vilobelimab): On April 4, 2023, the FDA issued (latest update April 12, 2023) an EUA for the use of GOHIBIC to treat certain hospitalized adult patients with severe COVID-19 illness.Convalescent plasma: On August 23, 2020, the FDA issued (latest update December 28, 2021) an EUA for the use of COVID-19 convalescent plasma for treating COVID-19 in hospitalized patients.Through the NCTAP, Medicare will provide an enhanced payment through September 30, 2023, for eligible inpatient cases that use certain new products with current FDA approval or emergency use authorization (EUA) to treat COVID-19, including the following: ![]() The NCTAP, designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments, is effective from November 2, 2020, until September 30, 2023. The enhanced payments described on this page will end on September 30, 2023.ĬMS issued an Interim Final Rule with Comment Period that established the New COVID-19 Treatments Add-on Payment (NCTAP) under the Medicare Inpatient Prospective Payment System (IPPS). ![]() Review this page for information about Medicare payment during and after the PHE. View Infectious diseases for a list of waivers and flexibilities that were in place during the PHE. The COVID-19 public health emergency (PHE) ended at the end of the day on May 11, 2023. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |